Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL. Grupp SA, Maude SL, Rives S, Hiramatsu H, et al. J Clin Oncol 2026;44:2999-3005.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Grupp SA, Maude SL, Rives S, Hiramatsu H, et al. Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL. J Clin Oncol 2026;44:2999-3005.
PMID: 42525896